Key result
In a canine model, selective COX-2 inhibition with celecoxib did not alter time to occlusive thrombus formation compared with controls (77.7 vs 93.0 minutes) but abolished the protective effect of COX-1 inhibition.
Why the study?
Does selective COX-2 inhibition with celecoxib alter time to occlusive thrombus formation and vascular tone in a canine model of coronary thrombosis?
Population
Dogs with circumflex coronary artery thrombosis induced by vascular electrolytic injury
Comparison
Oral celecoxib or high-dose aspirin, or oral HDA… vs Controls (no treatment) or HDA-ER alone
Design
Preclinical
Authors
Loading...
No immediate change to COX-2 inhibitor use indicated; extends mechanistic insights from canine model but leaves clinical translation open.
Does selective COX-2 inhibition with celecoxib alter time to occlusive thrombus formation and vascular tone in a canine model of coronary thrombosis?
Absolute Event Rate: 77.7% vs 93%
Selective COX-2 inhibition suppresses the protective effects of prostacyclin, promoting thrombosis and impairing vasodilation in a canine model, highlighting potential cardiovascular risks of COX-2 inhibitors.
Hennan et al. (2001) studied Coronary artery thrombosis (animal model). Celecoxib vs. Controls was evaluated on Time to occlusive thrombus formation. In a canine model, selective COX-2 inhibition with celecoxib did not alter time to occlusive thrombus formation compared with controls (77.7 vs 93.0 minutes) but abolished the protective effect of COX-1 inhibition.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: